Antimicrobial dosing in neonates

References

• Hornik CP, Fort P, Clark RH, et al. Early and late onset sepsis in very-low-birth-weight infants from a large group of neonatal intensive care units. Early Hum Dev. 2012;88(Suppl 2):S69–S74.
   PubMedGoogle Scholar
• Stoll BJ, Hansen NI, Sanchez PJ, et al. Early onset neonatal sepsis: the burden of group B Streptococcal and E. coli disease continues. Pediatrics. 2011;127(5):817–826.
   PubMed Web of Science ®Google Scholar
• Lutsar I, Chazallon C, Carducci FI, et al. Current management of late onset neonatal bacterial sepsis in five European countries. Eur J Pediatr. 2014;173(8):997–1004.
   PubMed Web of Science ®Google Scholar
• Versporten A, Bielicki J, Drapier N, et al. The Worldwide Antibiotic Resistance and Prescribing in European Children (ARPEC) point prevalence survey: developing hospital-quality indicators of antibiotic prescribing for children. J Antimicrob Chemother. 2016;71(4):1106–1117.
   PubMed Web of Science ®Google Scholar
• Spyridis N, Syridou G, Goossens H, et al. Variation in paediatric hospital antibiotic guidelines in Europe. Arch Dis Child. 2016;101(1):72–76.
   PubMed Web of Science ®Google Scholar
• Schulman J, Dimand RJ, Lee HC, et al. Neonatal intensive care unit antibiotic use. Pediatrics. 2015;135(5):826–833.
   PubMed Web of Science ®Google Scholar
• Cuzzolin L, Agostino R. Off-label and unlicensed drug treatments in Neonatal Intensive Care Units: an Italian multicentre study. Eur J Clin Pharmacol. 2016;72(1):117–123.
   PubMed Web of Science ®Google Scholar
• Silva J, Flor-de-Lima F, Soares H, et al. Off-label and unlicensed drug use in neonatology: reality in a Portuguese university hospital. Acta Med Port. 2015;28(3):297–306.
   PubMed Web of Science ®Google Scholar
• Porta A, Esposito S, Menson E, et al. Off-label antibiotic use in children in three European countries. Eur J Clin Pharmacol. 2010;66(9):919–927.
   PubMed Web of Science ®Google Scholar
• Metsvaht T, Nellis G, Varendi H, et al. High variability in the dosing of commonly used antibiotics revealed by a Europe-wide point prevalence study: implications for research and dissemination. BMC Pediatr. 2015;15:41.
   PubMed Web of Science ®Google Scholar
• Leroux S, Zhao W, Betremieux P, et al. Therapeutic guidelines for prescribing antibiotics in neonates should be evidence-based: a French national survey. Arch Dis Child. 2015;100(4):394–398.
   PubMed Web of Science ®Google Scholar
• British National Formulary for Children 2015–2016, BMJ Group. The Royal Pharmaceutical Society of Great Britain and RCPCH Publications Ltd 2016.
   Google Scholar
• Neofax 2011, Thomson Reuters Clinical Editorial Staff, 24th edition.
   Google Scholar
• Allegaert K. Tailored tools to improve pharmacotherapy in infants. Expert Opin Drug Metab Toxicol. 2014;10(8):1069–1078.
   PubMed Web of Science ®Google Scholar
• Allegaert K, Langhendries JP, van den Anker JN. Educational paper: do we need neonatal clinical pharmacologists? Eur J Pediatr. 2013;172(4):429–435.
   PubMed Web of Science ®Google Scholar
• Samardzic J, Allegaert K, Wilbaux M, et al. Quantitative clinical pharmacology practice for optimal use of antibiotics during the neonatal period. Expert Opin Drug Metab Toxicol. 2016;12(4):367–375.
   PubMed Web of Science ®Google Scholar
• de Cock RF, Piana C, Krekels EH, et al. The role of population PK-PD modelling in paediatric clinical research. Eur J Clin Pharmacol. 2011;67(Suppl 1):5–16.
   PubMed Web of Science ®Google Scholar
• Autmizguine J, Benjamin DK Jr., Smith PB, et al. Pharmacokinetic studies in infants using minimal-risk study designs. Curr Clin Pharmacol. 2014;9(4):350–358.
   PubMedGoogle Scholar
• Samardzic J, Turner MA, Bax R, et al. Neonatal medicines research: challenges and opportunities. Expert Opin Drug Metab Toxicol. 2015;11(7):1041–1052.
   PubMed Web of Science ®Google Scholar
• Kaguelidou F, Turner MA, Choonara I, et al. Randomized controlled trials of antibiotics for neonatal infections: a systematic review. Br J Clin Pharmacol. 2013;76(1):21–29.
   PubMed Web of Science ®Google Scholar
• Wang J, Avant D, Green D, et al. A survey of neonatal pharmacokinetic and pharmacodynamic studies in pediatric drug development. Clin Pharmacol Ther. 2015;98(3):328–335.
   PubMed Web of Science ®Google Scholar
• Pansieri C, Bonati M, Choonara I, et al. Neonatal drug trials: impact of EU and US paediatric regulations. Arch Dis Child Fetal Neonatal Ed. 2014;99(5):F438.
   PubMed Web of Science ®Google Scholar
• Wilbaux M, Fuchs A, Samardzic J, et al. Pharmacometric approaches to personalize use of primarily renally eliminated antibiotics in preterm and term neonates. J Clin Pharmacol. 2016;56(8):909–935.
   PubMed Web of Science ®Google Scholar
• Jacqz-Aigrain E. Drug policy in Europe research and funding in neonates: current challenges, future perspectives, new opportunities. Early Hum Dev. 2011;87(suppl 1):S27–S30.
   PubMed Web of Science ®Google Scholar
• Zhao W, Hill H, Le Guellec C, et al. Population pharmacokinetics of ciprofloxacin in neonates and young infants less than three months of age. Antimicrob Agents Chemother. 2014;58(11):6572–6580.
   PubMed Web of Science ®Google Scholar
• Tremoulet A, Le J, Poindexter B, et al. Characterization of the population pharmacokinetics of ampicillin in neonates using an opportunistic study design. Antimicrob Agents Chemother. 2014;58(6):3013–3020.
   PubMed Web of Science ®Google Scholar
• Smith PB, Cohen-Wolkowiez M, Castro LM, et al. Population pharmacokinetics of meropenem in plasma and cerebrospinal fluid of infants with suspected or complicated intra-abdominal infections. Pediatr Infect Dis J. 2011;30(10):844–849.
   PubMed Web of Science ®Google Scholar
• Lutsar I, Trafojer UM, Heath PT, et al. Meropenem vs standard of care for treatment of late onset sepsis in children of less than 90 days of age: study protocol for a randomised controlled trial. Trials. 2011;12:215.
   PubMed Web of Science ®Google Scholar